Scholarlink

<p>Diffuse low-grade glioma, MAPK pathway–altered (DLGG–MAPK), is a recently defined tumor entity characterized by genetic alterations activating the MAPK signaling cascade. While <i>BRAF</i> and <i>FGFR</i> alterations are most frequently reported, the biological and clinical significance of other MAPK-activating events remains poorly understood. We report a 25-year-old woman with a right temporal lobe tumor harboring a novel <i>CUX1</i>::<i>MET</i> fusion. The lesion was initially detected at age 10 during neuroimaging performed for a transient headache and subsequently followed an indolent clinical course for approximately 15 years before manifesting with acute hemorrhage. Histologically, the tumor showed diffuse infiltration with oligodendroglioma-like morphology, absence of high-grade features, and a low proliferative index. Molecular analysis identified an in-frame <i>CUX1</i>::<i>MET</i> fusion retaining the MET kinase domain, resulting in exon 14 skipping and activation of the MAPK pathway. Despite the presence of a MET alteration typically associated with aggressive tumors, the lesion demonstrated prolonged indolence and low-grade biological behavior. To our knowledge, this is the first case report demonstrating the presence of a <i>CUX1</i>::<i>MET</i> fusion in DLLG-MAPK. This case expands the molecular spectrum of DLGG–MAPK and provides novel insight into the biological heterogeneity of MET-driven gliomas, suggesting that MET fusion alone is insufficient to confer high-grade behavior in this tumor context.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CUX1::MET fusion defines an indolent subtype of diffuse low-grade glioma, MAPK pathway–altered

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月3日

查看全文
  • Hiroaki Nagashima,
  • Yasuhide Takeuchi,
  • Naoe Jimbo,
  • Hadzki Matsuda,
  • Shiro Kimbara,
  • Kazuhiro Tanaka,
  • Takashi Sasayama

摘要

Diffuse low-grade glioma, MAPK pathway–altered (DLGG–MAPK), is a recently defined tumor entity characterized by genetic alterations activating the MAPK signaling cascade. While BRAF and FGFR alterations are most frequently reported, the biological and clinical significance of other MAPK-activating events remains poorly understood. We report a 25-year-old woman with a right temporal lobe tumor harboring a novel CUX1::MET fusion. The lesion was initially detected at age 10 during neuroimaging performed for a transient headache and subsequently followed an indolent clinical course for approximately 15 years before manifesting with acute hemorrhage. Histologically, the tumor showed diffuse infiltration with oligodendroglioma-like morphology, absence of high-grade features, and a low proliferative index. Molecular analysis identified an in-frame CUX1::MET fusion retaining the MET kinase domain, resulting in exon 14 skipping and activation of the MAPK pathway. Despite the presence of a MET alteration typically associated with aggressive tumors, the lesion demonstrated prolonged indolence and low-grade biological behavior. To our knowledge, this is the first case report demonstrating the presence of a CUX1::MET fusion in DLLG-MAPK. This case expands the molecular spectrum of DLGG–MAPK and provides novel insight into the biological heterogeneity of MET-driven gliomas, suggesting that MET fusion alone is insufficient to confer high-grade behavior in this tumor context.